Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Nxera Pharma and PrecisionLife Expand Strategic R&D Partnership into New Therapeutic Area
Details : The strategic R&D partnership for the auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
Details : Under the agreement, PrecisionLife will apply its combinatorial analytics platform to patient datasets to find multiple new therapeutic targets for development by Ono.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?